[go: up one dir, main page]

WO2012012271A3 - Novel glycosylated polypeptides - Google Patents

Novel glycosylated polypeptides Download PDF

Info

Publication number
WO2012012271A3
WO2012012271A3 PCT/US2011/044081 US2011044081W WO2012012271A3 WO 2012012271 A3 WO2012012271 A3 WO 2012012271A3 US 2011044081 W US2011044081 W US 2011044081W WO 2012012271 A3 WO2012012271 A3 WO 2012012271A3
Authority
WO
WIPO (PCT)
Prior art keywords
neu5gc
glycosylated polypeptides
compositions
competitor
substantially reduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/044081
Other languages
French (fr)
Other versions
WO2012012271A2 (en
Inventor
Ajit Varki
Darius Ghaderi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sialix Inc
Original Assignee
Sialix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sialix Inc filed Critical Sialix Inc
Publication of WO2012012271A2 publication Critical patent/WO2012012271A2/en
Anticipated expiration legal-status Critical
Publication of WO2012012271A3 publication Critical patent/WO2012012271A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Provided herein are glycosylated polypeptide compositions with substantially reduced Neu5Gc content. The glycosylated polypeptides compositions with substantially reduced Neu5Gc content can be obtained from cell sources cultured with Neu5Gc competitor or from non-human animal sources fed a diet supplemented with Neu5Gc competitor. Also provided herein are methods of treating a human subject with said compositions.
PCT/US2011/044081 2010-07-19 2011-07-14 Novel glycosylated polypeptides Ceased WO2012012271A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36572710P 2010-07-19 2010-07-19
US61/365,727 2010-07-19

Publications (2)

Publication Number Publication Date
WO2012012271A2 WO2012012271A2 (en) 2012-01-26
WO2012012271A3 true WO2012012271A3 (en) 2014-03-27

Family

ID=45497386

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/044081 Ceased WO2012012271A2 (en) 2010-07-19 2011-07-14 Novel glycosylated polypeptides

Country Status (1)

Country Link
WO (1) WO2012012271A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017044811A1 (en) * 2015-09-11 2017-03-16 Bruce Andrien Recombinant glycosylated eculizumab and eculizumab variants
WO2018024770A1 (en) 2016-08-03 2018-02-08 Formycon Ag Production of biosimilar ustekinumab in cho cells
CN114167060B (en) * 2021-11-25 2022-08-05 辽宁师范大学 Liver cancer biomarker and kit for detecting liver cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090099073A1 (en) * 2001-12-21 2009-04-16 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2010030666A2 (en) * 2008-09-09 2010-03-18 The Regents Of The University Of California Elimination of a contaminating non-human sialic acid by metabolic competition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090099073A1 (en) * 2001-12-21 2009-04-16 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2010030666A2 (en) * 2008-09-09 2010-03-18 The Regents Of The University Of California Elimination of a contaminating non-human sialic acid by metabolic competition

Also Published As

Publication number Publication date
WO2012012271A2 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
WO2011079314A8 (en) Compositions and methods for the increased production of isoprene and other products with 6 - phosphogluconolactonase (pgl)
EP2534257A4 (en) Methods for identifying and isolating cells expressing a polypeptide
GB201122047D0 (en) Transgenic animals
NZ701791A (en) Cell culture compositions and methods for polypeptide production
MX354993B (en) Prevention of disulfide bond reduction during recombinant production of polypeptides.
EP2808393A3 (en) Fucosylation-deficient cells
WO2010011735A3 (en) Modified bovine g-csf polypeptides and their uses
EP4269602A3 (en) Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
IL222507A0 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2010068897A3 (en) Stem cell enhanced protein products and uses thereof
SG10201900003WA (en) Non-human animals having a humanized b-cell activating factor gene
SG10201811701YA (en) Non-human animals having a humanized a proliferation-inducing ligand gene
IL226501A0 (en) Protein delivery from stem cell microcarriers
IL269197A (en) Control of total afucosylated glycoforms of antibodies produced in cell culture
MX349301B (en) Modified bovine somatotropin polypeptides and their uses.
MX2020012356A (en) Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins.
MX2012006980A (en) Modified porcine somatotropin polypeptides and their uses.
MX2011012623A (en) Casb7439 constructs.
EP2189529A4 (en) Recombinant mammalian cells, method of producing recombinant mammalian cells and method of producing target protein
WO2012012271A3 (en) Novel glycosylated polypeptides
EP2719764A4 (en) Expression vector for animal cells including csp-b 5'-sar factor and method for producing recombinant proteins using same
MX2012001018A (en) Beta cell marker antibody.
WO2010078580A3 (en) Immunotherapy for contact dermatitis using co-signal regulation
SG181862A1 (en) Protein display
WO2012082509A3 (en) Biomarkers for enhanced protein production

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11810191

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 11810191

Country of ref document: EP

Kind code of ref document: A2